Potenzial hämatopoetischer Stammzellen als Ausgangsmaterial für Arzneimittel für neuartige Therapien

Abstract

Individualized, (stem) cell-based therapies of congenital and acquired illnesses are among the most exciting medical challenges of the twenty-first century. Before the full potential of such therapies can be achieved, many basic scientific and biotechnological questions remain to be answered. What is the ideal source for the generation of such cellular drugs is one of those issues. In many respects, hematopoietic stem cells fulfill the requirements for stem cells as starting material for novel cellular therapeutics, including the simple access to large amounts of stem cells, the availability of good phenotypic markers for their prospective isolation, and an extensive body of knowledge about the in vitro manipulation of these cells. This manuscript discusses the general and specific usability of hematopoietic stem cells as starting material for novel cellular therapeutics and presents some examples of hematological and nonhematological therapeutic approaches which are based on hematopoietic stem cells.

Zika virus infection studies with CD34+ hematopoietic and megakaryocyte‐erythroid progenitors, red blood cells and platelets

“…Consequently, the data suggest that ZIKV transmission via purified CD34 + is unlikely. Purified CD34 + HSPCs are often used as starting material for advanced therapy medicinal products (ATMPs) . However, purified CD34 + HSCPs are rarely used for hematopoietic reconstitution, whereas unprocessed grafts, containing residual RBCs, high amounts of leukocytes and plasma, are preferentially transfused.…”

“…Purified CD34 + HSPCs are often used as starting material for advanced therapy medicinal products (ATMPs). 89 However, purified CD34 + HSCPs are rarely used for hematopoietic reconstitution, whereas unprocessed grafts, containing residual RBCs, high amounts of leukocytes and plasma, are preferentially transfused. Thus, for unprocessed hematopoietic stem cell transplants the risk of ZIKV transmission via residual ZIKV-susceptible cells or plasma still remains.…”